Phenoxybenzamine Hydrochloride is a human prescription drug labeled by 'Amneal Pharmaceuticals Ny Llc'. National Drug Code (NDC) number for Phenoxybenzamine Hydrochloride is 60219-1502. This drug is available in dosage form of Capsule. The names of the active, medicinal ingredients in Phenoxybenzamine Hydrochloride drug includes Phenoxybenzamine Hydrochloride - 10 mg/1 . The currest status of Phenoxybenzamine Hydrochloride drug is Active.

Phenoxybenzamine hydrochloride phenoxybenzamine hydrochloride phenoxybenzamine hydrochloride phenoxybenzamine alcohol ammonia butyl alcohol d&c red no. 33 fd&c red no. 3 ferric oxide yellow gelatin, unspecified isopropyl alcohol lactose monohydrate potassium hydroxide propylene glycol shellac silicon dioxide sodium lauryl sulfate titanium dioxide red cap and red body amneal;1502

Drug interactions 2 – phenoxybenzamine hydrochloride may interact with compounds that stimulate both alpha- and beta- adrenergic receptors (i.e. epinephrine) to produce an exaggerated hypotensive response and tachycardia (see warning ). phenoxybenzamine hydrochloride blocks hyperthermia production by levarterenol, and blocks hypothermia production by reserpine.

Indication and usage phenoxybenzamine hydrochloride capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. if tachycardia is excessive, it may be necessary to use a beta -blocking agent concomitantly.

Warning phenoxybenzamine hydrochloride-induced alpha -adrenergic blockade leaves beta -adrenergic receptors unopposed. compounds that stimulate both types of receptors may, therefore, produce an exaggerated hypotensive response and tachycardia.

Dosage and administration the dosage should be adjusted to fit the needs of each patient. small initial doses should be slowly increased until the desired effect is obtained or the side effects from blockade become troublesome. after each increase, the patient should be observed on that level before instituting another increase . the dosage should be carried to a point where symptomatic relief and/or objective improvement are obtained, but not so high that the side effects from blockade become troublesome. initially, 10 mg of phenoxybenzamine hydrochloride twice a day. dosage should be increased every other day, usually to 20 mg to 40 mg 2 or 3 times a day, until an optimal dosage is obtained, as judged by blood pressure control. long-term use of phenoxybenzamine is not recommended (see precautions - carcinogenesis and mutagenesis ).

Contraindications conditions where a fall in blood pressure may be undesirable; hypersensitivity to the phenoxybenzamine hydrochloride capsules, or any of its components.

Adverse reactions the following adverse reactions have been observed, but there are insufficient data to support an estimate of their frequency. autonomic nervous system*: postural hypotension, tachycardia, inhibition of ejaculation, nasal congestion, miosis. *these so-called “side effects” are actually evidence of adrenergic blockade and vary according to the degree of blockade. miscellaneous: gastrointestinal irritation, drowsiness, fatigue. to report suspected adverse reactions, contact amneal pharmaceuticals at 1-877-835-5472 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Drug interactions 2 – phenoxybenzamine hydrochloride may interact with compounds that stimulate both alpha- and beta- adrenergic receptors (i.e. epinephrine) to produce an exaggerated hypotensive response and tachycardia (see warning ). phenoxybenzamine hydrochloride blocks hyperthermia production by levarterenol, and blocks hypothermia production by reserpine.

Pregnancy - teratogenic effects adequate reproductive studies in animals have not been performed with phenoxybenzamine hydrochloride. it is also not known whether phenoxybenzamine hydrochloride can cause fetal harm when administered to a pregnant woman. phenoxybenzamine hydrochloride should be given to a pregnant woman only if clearly needed.

Pediatric use safety and effectiveness in pediatric patients have not been established.

Overdosage symptoms - these are largely the result of blocking of the sympathetic nervous system and of the circulating epinephrine. they may include postural hypotension, resulting in dizziness or fainting; tachycardia, particularly postural; vomiting; lethargy; shock. treatment when symptoms and signs of overdosage exist, discontinue phenoxybenzamine hydrochloride capsules. treatment of circulatory failure, if present, is a prime consideration. in cases of mild overdosage, recumbent position with legs elevated usually restores cerebral circulation. in the more severe cases, the usual measures to combat shock should be instituted. usual pressor agents are not effective. epinephrine is contraindicated because it stimulates both alpha - and beta - receptors; since alpha- receptors are blocked, the net effect of epinephrine administration is vasodilation and a further drop in blood pressure (epinephrine reversal). the patient may have to be kept flat for 24 hours or more in the case of overdose, as the effect of the drug is prolonged. leg bandages and an abdominal binder may shorten the period of disability. intravenous infusion of levarterenol bitartrate** may be used to combat severe hypotensive reactions, because it stimulates alpha - receptors primarily. although phenoxybenzamine hydrochloride is an alpha -adrenergic blocking agent, a sufficient dose of levarterenol bitartrate will overcome this effect. the oral ld 50 for phenoxybenzamine hydrochloride is approximately 2,000 mg/kg in rats and approximately 500 mg/kg in guinea pigs.

Description each phenoxybenzamine hydrochloride capsule, usp with red cap and body, is imprinted with “amneal” on cap and “1502” on body, and contains 10 mg of phenoxybenzamine hydrochloride, usp. inactive ingredients consist of colloidal silicon dioxide, d&c red 33, fd & c red 3, gelatin, iron oxide yellow, lactose monohydrate and sodium lauryl sulfate. the capsule is imprinted with white pharmaceutical ink which contains butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, shellac, strong ammonia solution and titanium dioxide. phenoxybenzamine hydrochloride is chemically known as n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl) benzylamine hydrochloride. its molecular formula is c 18 h 22 clno·hcl. the chemical structure is: phenoxybenzamine hydrochloride, usp is a white to almost white crystalline powder with a molecular weight of 340.29 g/mol, which melts between 136° and 141°c. it is freely soluble in ethanol (96%) and insoluble in diethyl ether. fda approved organic impurity specification differs from the usp. 1

Clinical pharmacology phenoxybenzamine hydrochloride is a long-acting, adrenergic, alpha -receptor-blocking agent, which can produce and maintain “chemical sympathectomy” by oral administration. it increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. it has no effect on the parasympathetic system. 20 percent to 30 percent of orally administered phenoxybenzamine appears to be absorbed in the active form 1 . the half-life of orally administered phenoxybenzamine hydrochloride is not known; however, the half-life of intravenously administered phenoxybenzamine hydrochloride is approximately 24 hours. demonstrable effects with intravenous administration persist for at least 3 to 4 days, and the effects of daily administration are cumulative for nearly a week 1 .

Carcinogenesis and mutagenesis case reports of carcinoma in humans after long-term treatment with phenoxybenzamine have been reported. hence long-term use of phenoxybenzamine is not recommended 3, 4 . carefully weigh the benefits and risks before prescribing phenoxybenzamine hydrochloride. phenoxybenzamine hydrochloride showed in vitro mutagenic activity in the ames test and mouse lymphoma assay; it did not show mutagenic activity in vivo in the micronucleus test in mice. in rats and mice, repeated intraperitoneal administration of phenoxybenzamine hydrochloride (three times per week for up to 52 weeks) resulted in peritoneal sarcomas. chronic oral dosing in rats (for up to 2 years) produced malignant tumors of the small intestine and non-glandular stomach, as well as ulcerative and/or erosive gastritis of the glandular stomach. whereas squamous cell carcinomas of the non-glandular stomach were observed at all tested doses of phenoxybenzamine hydrochloride, there was a no-observed-effe Read more...

How supplied phenoxybenzamine hydrochloride capsules usp, 10 mg are supplied as size ‘3’ red colored transparent hard gelatin capsule, imprinted with “amneal” on cap and “1502” on body with white ink containing white to off-white powder. they are available as follows: bottles of 100: ndc 60219-1502-1

Principal display panel ndc 60219-1502-1 phenoxybenzamine hydrochloride capsules usp, 10 mg 100 capsules rx only amneal pharmaceuticals llc 1